Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (ABOUND 70+)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02151149
Recruitment Status : Completed
First Posted : May 30, 2014
Results First Posted : September 24, 2018
Last Update Posted : September 24, 2018
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:
Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Carcinoma Squamous Cell Carcinoma Adenocarcinoma Carcinoma, Large Cell Lung Neoplasm Drug: nab-paclitaxel Drug: Carboplatin Phase 4

Detailed Description:
This is a Phase IV, randomized, open-label, multicenter study of continuous weekly versus weekly times three with one-week break nab-paclitaxel in combination with carboplatin as first-line treatment in elderly subjects (≥ 70 years old) with advanced non small cell lung cancer who have not received prior chemotherapy for their advanced disease and are not candidates for curative surgery or radiation therapy. The primary study endpoint is the percentage of subjects with either peripheral neuropathy or myelosuppression adverse events. Patients will continue treatment until they develop progressive disease, unacceptable side-effects or wish to withdraw from the study, according to local standard of care. Patients will have radiographic evaluations every 6 weeks while on treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 143 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)
Actual Study Start Date : June 9, 2014
Actual Primary Completion Date : July 14, 2017
Actual Study Completion Date : July 14, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)
nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
Drug: nab-paclitaxel
Other Name: Abraxane

Drug: Carboplatin
Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)
nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
Drug: nab-paclitaxel
Other Name: Abraxane

Drug: Carboplatin



Primary Outcome Measures :
  1. Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values [ Time Frame: From the date of the first dose of investigational product (IP) until 28 days after the last dose of IP; up to data cut-off date of 20 November 2016; The median treatment duration for Arms A and B were 3.04 months and 5.17 months respectively. ]
    Peripheral neuropathy (sensory or motor) assessment was done at screening, on Days 1, 8, 15 of every treatment cycle, at the End-of-Treatment visit and at the 28-day Follow-up Visit. Changes in neuropathy grade from baseline was reported as an AE as assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Myelosuppression in participants receiving chemotherapy may have manifested as neutropenia, thrombocytopenia, or anemia. Grade 3 neutropenia including an absolute neutropenia count (ANC) of 500 to 1,000 cells/mm^3; anemia hemoglobain levels (Hgb) <8.0 - 6.5 g/dL; <4.9 - 4.0 mmol/L; <80 - 65 g/L; transfusion indicated; and thrombocytopenia with platelet levels <100,000 cells/mm^3.


Secondary Outcome Measures :
  1. Number of Participants With Treatment Emergent Adverse Events During the Treatment Period [ Time Frame: From the date of the first dose of IP until 28 days after the last dose of IP; up to a later data cut-off date of 14 July 2017; maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively. ]

    Treatment-emergent adverse events (TEAEs) were defined as any AE or serious adverse event (SAE) that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP. Any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and based on the scale:

    Grade 1 = Mild - transient or mild discomfort; Grade 2 = Moderate - mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required; Grade 3 = Severe - marked limitation in activity, assistance usually required; medical intervention required, hospitalization is possible; Grade 4 = Life threatening - extreme limitation in activity, assistance required; medical intervention, hospitalization or hospice care probable; Grade 5 = death.


  2. Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn [ Time Frame: From the date of the first dose of IP until 28 days after the last dose of IP; up to a later data cut-off date of 14 July 2017 the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively ]
    The percentage of participants with at least 1 TEAE with action taken as studydrug withdrawn during the treatment period of the trial was assessed throughout the conduct of the study. Study drug withdrawn (treatment permanently discontinued) was attributed to the part in which the onset of the adverse event took place.

  3. Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study [ Time Frame: From day 1 of study treatment to the end date of study treatment; up to data cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively ]
    Dose intensity was the cumulative dose divided by the dosing period in weeks.

  4. Dose Intensity Per Week of Carboplatin During the Entire Study [ Time Frame: From day 1 of study treatment to the end date of study treatment; up to data cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively ]
    Dose intensity for carboplatin was the cumulative dose divided by the dosing period in weeks."

  5. Percentage of Participants With Dose Reductions During the Entire Study [ Time Frame: From the first dose of study treatment to discontinuation date of study treatment; up to date cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively ]
    A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.

  6. Percentage of Participants With a Dose Delay During the Entire Study [ Time Frame: From the first dose of study treatment to discontinuation date of study treatment; up to date cut off date of 16 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively ]
    A dose delay occurred when the dose assigned at a visit was held compared to the previous visit. Dose delays were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.

  7. Kaplan Meier Estimate of Progression-Free Survival (PFS) [ Time Frame: From first dose of IP to the date of disease progression; up to a later clinical cut-off date of 14 July 2017; for Arms A and B participants were followed for PFS for 31 months and 20 months respectively ]
    Progression-free survival was defined as the time in months from day 1 of treatment to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. RECIST V1.1 criteria includes: - Complete Response (CR) is the disappearance of all target lesions; - Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease (PD); - Progressive Disease is at least a 20% increase in the sum of diameters of target lesions from nadir

  8. Kaplan Meier Estimate of Overall Survival (OS) [ Time Frame: From first dose of IP to the date of death due to any cause; up to a later clinical cut-off date of 14 July 2017; for Arms A and B participants were followed for OS for 31 months and 33 months respectively ]
    Overall survival was defined as the time in months between day 1 of treatment and death from any cause). Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact.

  9. Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria [ Time Frame: From the first dose of IP to the date of documented first response; up to the data cut-off date of 14 July 2017; maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively. ]
    Overall response rate (ORR) was defined as the percentage of participants who had radiologic CR or PR compared to baseline (radiographic evaluation on the day of or within 28 days prior to randomization) according to RECIST Version 1.1 criteria as determined by the investigator, which was confirmed by repeated radiologic assessment performed no less than 28 days after the criteria for response were first met and occurred between Day 1 of treatment and the start of subsequent anticancer therapy, death or study discontinuation. A complete response and partial response per RECIST V 1.0 criteria was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of diameters of target lesions from baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: -

  • Inclusion Criteria: -

    1. Age ≥ 70 years at the time of signing the Informed Consent Form.
    2. Understand and voluntarily provide written informed consent prior to the conduct of any study related assessments/procedures.
    3. Able to adhere to the study visit schedule and other protocol requirements.
    4. Histologically or cytologically confirmed locally advanced or metastatic non small cell lung cancer who are not candidates for curative surgery or radiation therapy.
    5. No other current active malignancy requiring anticancer therapy.
    6. Radiographically documented measurable disease per RECIST v 1.1
    7. No prior chemotherapy for the treatment of metastatic disease. Adjuvant chemotherapy is permitted providing that cytotoxic chemotherapy was completed 12 months prior to signing the informed consent form (ICF) and without disease recurrence. Participans with previously known epidermal growth factor receptor mutation or anaplastic lymphoma kinase gene translocation must have failed or had intolerance to one treatment with epidermal growth factor receptor tyrosine kinase inhibitor or anaplastic lymphoma kinase inhibitor therapy, respectively.
    8. Absolute neutrophil count ≥ 1500 cells/cubic millimetre.
    9. Platelets ≥ 100,000 cells/cubic millimetre.
    10. Hemoglobin ≥ 9 grams/decilitre.
    11. Aspartate transaminase/serum glutamic oxaloacetic transaminase/ alanine transaminase/serum glutamic pyruvic transaminase ≤ 2.5 × upper limit of normal range or ≤ 5.0 × upper limit of normal range if liver metastases.
    12. Total bilirubin ≤ 1.5 millilitre/decilitre (unless there is a known history of Gilberts Syndrome).
    13. Creatinine clearance > 40 millilitre/minute calculated using Cockcroft-Gault equation (if renal impairment is suspected 24 hour urine collection for measurement is required).
    14. Eastern Cooperative Oncology Group performance status 0 or 1.
    15. Females who (1) have undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have been naturally postmenopausal for at least 24 consecutive months (ie, has not had menses at any time during the preceding 24 consecutive months).
    16. Male subjects must: Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following study drug discontinuation, even if he has undergone a successful vasectomy.

      Exclusion Criteria:

  • 1. Evidence of active brain metastases, including leptomeningeal involvement (prior evidence of brain metastasis are permitted only if treated and stable and off therapy for ≥ 4 weeks prior to signing Informed consent form. Magnetic Resonance Imaging of the brain (or Computed Tomography scan w/contrast) is preferred for diagnosis.

    2. History of leptomeningeal disease. 3. Only evidence of disease is non measurable. 4. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology Criteria for Adverse Events v4.0).

    5. Participant has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting investigational product, and/or from whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.

    6. Venous thromboembolism within 1 month prior to signing informed consent form.

    7. Current congestive heart failure (New York Heart Association Class II-IV). 8. History of the following within 6 months prior to first administration of a study drug: a myocardial infarction, severe/unstable angina pectoris,coronary/peripheral artery bypass graft, New York Heart Association Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant Electrocardiogram abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder.

    9. Participant has a known infection with hepatitis B or C, or history of human immunodeficiency virus infection, or participant is receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.

    10. Participant has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.

    11.History of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or pulmonary hypersensitivity pneumonitis.

    12. Treatment with any investigational product within 28 days prior to signing the informed consent form.

    13. History of allergy or hypersensitivity to nab-paclitaxel or carboplatin. 14. Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices. 15. Any other clinically significant medical condition, psychiatric illness, and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol or which, in the views of investigator, preclude combination chemotherapy.

    16. Participant has any other malignancy within 5 years prior to randomization. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer Tumor, Lymph Node, Metastatic (TNM stage of T1a or T1b). All treatment of which should have been completed 6 months prior to signing Informed consent form.

    17. Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.

    18. Any medical condition that confounds the ability to interpret data from the study.

    19. Females who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02151149


  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
Arizona Clinical Research Center
Tucson, Arizona, United States, 85715
United States, Arkansas
Genesis Cancer Center
Hot Springs, Arkansas, United States, 71913
United States, California
Comprehensive Blood and Cancer Center
Bakersfield, California, United States, 93309
Saint Jude Heritage Medical Center
Fullerton, California, United States, 92835
Global Cancer Research Institute (GCRI), Inc.
Gilroy, California, United States, 95020
Ventura County Hematology-Oncology Specialists
Oxnard, California, United States, 93030
Central Coast Medical Oncology Corporation
Santa Maria, California, United States, 93454
University of California Los Angeles
Santa Monica, California, United States, 90404
United States, Colorado
Rocky Mountain Cancer Centers, LLP
Denver, Colorado, United States, 80218
St Mary's Hospital and Regional Medical Center
Grand Junction, Colorado, United States, 81501
United States, Florida
Lynn Cancer Institute
Boca Raton, Florida, United States, 33486
Baptist Cancer Inst
Jacksonville, Florida, United States, 32207
Ocala Oncology Center
Ocala, Florida, United States, 34471
Florida Hospital Cancer Institute
Orlando, Florida, United States, 32804
United States, Illinois
Northshore University Healthsystem Research Institute
Evanston, Illinois, United States, 60201
Oncology Specialists, S.C.
Niles, Illinois, United States, 60714
United States, Indiana
Franciscan St. Francis Health
Indianapolis, Indiana, United States, 46237
United States, Kansas
Cancer Center of Kansas
Wichita, Kansas, United States, 67214
United States, Kentucky
Western Kentucky Hematology and Oncology Group
Paducah, Kentucky, United States, 42003
United States, Louisiana
West Jeffersion Medical Center
Marrero, Louisiana, United States, 70072
Ochsner Medical Institutions
New Orleans, Louisiana, United States, 70123
United States, Maryland
Medstar Health Research Institute
Baltimore, Maryland, United States, 21237
United States, Massachusetts
Reliant Medical Group
Worcester, Massachusetts, United States, 01608
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202-268
United States, Nebraska
Nebraska Methodist Hospital
Omaha, Nebraska, United States, 68114
United States, New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Center for Cancer and Hematologic Disease
Cherry Hill, New Jersey, United States, 08003
Regional Cancer Care Associates LLC
East Brunswick, New Jersey, United States, 08816
Saint Barnabas Medical Center
Livingston, New Jersey, United States, 07039
Carol G Simon Cancer Center
Morristown, New Jersey, United States, 07962
Somerset Hematology-Oncology Associates
Somerville, New Jersey, United States, 08876
Regional Cancer Care Associates LLC- Sparta division
Sparta, New Jersey, United States, 07871
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10461
Brookdale University Hospital and Medical Center
Brooklyn, New York, United States, 11212
Broome Oncology, LLC
Johnson City, New York, United States, 13790
Clinical Research Alliance
Lake Success, New York, United States, 11042
SUNY Upstate Medical University Medicine Oncology
Syracuse, New York, United States, 13215
United States, North Carolina
Lineberger Cancer Center
Chapel Hill, North Carolina, United States, 27599
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Forsyth Memorial Hospital, Inc.
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
St Elizabeth Hospital
Youngstown, Ohio, United States, 44501
United States, Oklahoma
Cancer Centres of Southwest Okahoma Research
Lawton, Oklahoma, United States, 73505
United States, Oregon
Good Samaritan Hospital Corvalis
Corvallis, Oregon, United States, 97330
Oregon Health and Science University
Portland, Oregon, United States, 97210
United States, Pennsylvania
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States, 19104
Thomas Jefferson University Medical College
Philadelphia, Pennsylvania, United States, 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
United States, Texas
Texas Oncology, P.A.-Amarillo
Amarillo, Texas, United States, 79106
Baylor University Medical Center at Dallas
Dallas, Texas, United States, 75246
UTMB Galveston
Galveston, Texas, United States, 77555-0565
Texas Oncology, PA - Longview
Longview, Texas, United States, 75601
United States, Washington
Virginia Mason Cancer Center
Seattle, Washington, United States, 98101
Northwest Cancer Specialists, P.C.
Vancouver, Washington, United States, 98684
Sponsors and Collaborators
Celgene
Investigators
Layout table for investigator information
Study Director: Teng Jin Ong Celgene

Layout table for additonal information
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT02151149     History of Changes
Other Study ID Numbers: ABI-007-NSCL-005
First Posted: May 30, 2014    Key Record Dates
Results First Posted: September 24, 2018
Last Update Posted: September 24, 2018
Last Verified: August 2018
Keywords provided by Celgene:
NSCLC advanced non-small cell lung cancer squamous adenocarcinoma large cell carcinoma lung cancer elderly first line treatment abraxane carbo nab-paclitaxel
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Adenocarcinoma
Carcinoma, Large Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Paclitaxel
Albumin-Bound Paclitaxel
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action